Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Agouron Pharmaceuticals (AGPH) -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (4602)	6/29/1998 4:35:00 PM
From: Peter Singleton	Read Replies (1) \| Respond to of 6136

Rick, that was a strange release from Roche. So, they are targeting chemokine receptors that HIV uses to penetrate the host cell ... ok, what else is new, what are they bringing to the effort that's newsworthy at this point? Do you have an opinion of CCR5 as a target? There's a lot of stuff out there (6/19/98 Science, last fall's SciAm, etc.) that indicates it might. To summarize in non-technical language (the only language I can use as a non-scientist), it seems like GP120 is unlikely as a target, though the recent solving of the structure may offer some hope, so that leaves CD4 and the co-receptors. With the information about CCR5 deficient patients correlating with delayed or non-progression, it looks like a) a promising target, and b) CCR5 deficient folks don't appear to be immune compromised, so targeting CCR5 may not interfere with normal immune system function. Peter